RT journal article
T1 Bimekizumab: Short-Term Effectiveness and Safety in Real Clinical Practice in Andalucia, Spain
A1 Ruiz Villaverde, Ricardo
A1 Rodríguez-Fernández Freire, Lourdes
A1 Cebolla Verdugo, Marta
A1 Prados Carmona, Alvaro
A1 Hernández Montoya, Carlos
A1 Armario Hita, José Carlos
A1 Galán Gutiérrez, Manuel
A2 Cirugía
A2 Medicina
K1 psoriasis
K1 bimekizumab
K1 biological therapy
AB Introduction: Psoriasis, a chronic inflammatory skin disease, affects 2–10% of the populationglobally. Bimekizumab (BMK), a monoclonal antibody targeting IL-17, is a dual inhibitor ofIL17 A and F that has shown efficacy in treating moderate to severe plaque psoriasis. This real-worldevidence (RWE) study aims to assess BMK’s efficiency and safety in naïve and refractory patients.Material and methods: A retrospective analysis of a multicenter observational study included 22 patientstreated with BMK from April 2023 to February 2023 in five Andalusian hospitals. Ethicalapproval was obtained, and patients provided informed consent. Assessment criteria encompassedPsoriasis Area and Severity Index (PASI), body surface area (BSA), VAS pruritus, Dermatology LifeQuality Index (DLQI), and minimum disease activity (MDA) at 0, 4, 12, and 24 weeks. Results:Patients, predominantly with plaque psoriasis, exhibited significant improvements in PASI (baseline15.7 to 0.4 at week 16), BSA (baseline 20.7 to 0.43 at week 16), DLQI (baseline 17.93 to 0.43 at week 16),and pruritus (baseline 7.12 to 0.4 at week 16). At week 16, 95.4% achieved MDA. No safety concernsor treatment discontinuations were reported. Discussion: This RWE study aligns with pivotal clinicaltrials, confirming BMK’s efficacy and safety. Notably, BMK demonstrated rapid and sustainedpsoriasis clearance, even in challenging areas. The study’s limitations include a small sample size,suggesting the need for further exploration of patient-reported outcomes. Conclusion: Bimekizumabexhibited optimal efficacy and safety profiles in treating moderate to severe plaque psoriasis in areal-world setting. Rapid response, sustained clearance, and favorable safety outcomes contributeto improved patient experiences. Future research could delve into patient-reported outcomes andexpand sample sizes to enhance the understanding of BMK’s real-world effectiveness.
PB MDPI
SN 20751729
YR 2024
FD 2024
LK http://hdl.handle.net/10498/33643
UL http://hdl.handle.net/10498/33643
LA eng
DS Repositorio Institucional de la Universidad de Cádiz
RD 10-nov-2026